Biogen Drug Sends Tau Into Reverse: An Alzheimer’s Breakthrough In The Making?

Phase I study and open-label extension results show a big drop in tau levels, which are more closely linked to Alzheimer’s symptoms than amyloid beta – setting up hopes of success in an ongoing Phase II study.